HC Wainwright Reaffirms “Buy” Rating for PolyPid (NASDAQ:PYPD)

HC Wainwright restated their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research report released on Wednesday, Benzinga reports. They currently have a $14.00 price target on the stock.

PolyPid Trading Up 1.3 %

PYPD stock opened at $3.59 on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 1.95. PolyPid has a 12-month low of $2.95 and a 12-month high of $9.20. The stock has a market cap of $17.21 million, a price-to-earnings ratio of -0.28 and a beta of 1.32. The business’s 50-day moving average is $3.52 and its 200 day moving average is $4.07.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, August 14th. The company reported ($1.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.26. On average, sell-side analysts anticipate that PolyPid will post -4.39 EPS for the current fiscal year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.